The role of gene-environment interactions in the pathogenesis of depression is unclear. Previous studies addressed vulnerability for depression after childhood adversity and stressful life events among carriers of numerous specific genetic variants; however, the importance of individual genetic variants, the environmental exposures with which they interact, and the magnitude of the risk conveyed by these interactions remain elusive.
INTRODUCTION
Gene-environment interactions hypothesized to affect risk for depression have been investigated in numerous studies during the past 15 years. However, few certainties and clinically relevant insights have been achieved and the field is characterized by controversy (Munafò, 2015; Rutter, Thapar, and Pickles, 2009; Taylor et al., 2016; Zammit, Owen, & Lewis, 2010 ) with a continued need for improving our understanding of the role of gene-environment interactions in the development of depression (Dunn et al., 2015; Krishnan et al., 2010; Uher, 2014) . Meta-analytic reviews have addressed the need for greater attention to the type of exposures as well as age at exposure. Thus, the most recent meta-analysis of serotonin transporter linked polymorphic region (5-HTTLPR), stressful life events and depression report evidence for the existence of a gene-environment interaction; however, as the authors pointed out, many well-conducted studies did not observe the interaction (Sharpley, Palanisamy, Glyde, Dillingham, & Agnew, 2014) . In addition, a meta-analysis of the involvement of rs6265 in the brain-derived neurotropic factor (BDNF) gene in geneenvironment interaction for depression found more evidence for this genetic variant having an effect on risk for depression in relation to adult stressful life events than in relation to childhood adversities (Hosang, Shiles, Tansey, McGuffin, & Uher, 2014) . Such observations combined with the general knowledge of the complexity of brain maturation and changes in gene expression across the life course (Gogtay et al., 2004; Kang et al., 2011; Nord, Pattabiraman, Visel, & Rubenstein, 2015) suggest that it is essential to investigate geneenvironment interactions in specific contexts defined by the type of Depress Anxiety. 2017;34:845-855.
c 2017 Wiley Periodicals, Inc. 845 wileyonlinelibrary.com/journal/da environmental exposure, the timing of exposures during course of life, and the genetic variants with which they might interact. Associated with increased prevalence of depression (Massie, 2004; Mitchell et al., 2011; van't Spijker, Trijsburg, & Duivenvoorden, 1997) , posing a high risk of dying, often involving major surgery and adjuvant treatment with burdensome side effects, and having onset predominantly in late adulthood, we consider cancer to represent a homogenous life event.
Addressing methodological limitations of previous studies, including low statistical power and nonobjective assessment of stressful events, here we present an exposed-only study evaluating if six of the most investigated genetic variants were associated with pharmacologically as well as hospital-treated depression in a large, elderly population of cancer patients. The genetic variants investigated were the 5-HTTLPR including the rs25531, the rs6562 in the BDNF gene, the rs6295 in the serotonin-receptor 1A (HTR1A) gene, the rs4680 in the catechol-O-methyl transferase (COMT) gene, and the rs1360780 in the FK506-binding protein 5 (FKBP5) gene.
MATERIALS AND METHODS

Study population
The sample for this study was obtained from the Danish prospective cohort study: Diet, Cancer and Health (Tjonneland et al., 2007) . Briefly, between December 1993 and May 1997, all 160,725 people aged 50-64 who were born in Denmark, who had never had a diagnosis of cancer and who lived in selected municipalities in or near Aarhus and Copenhagen, the two major cities of Denmark, were invited to participate.
Fifty seven thousand fifty three participants were included and provided various biological materials, including blood samples, from which samples of purified DNA were stored.
For the current study, we identified all 7,641 participants with a first primary cancer diagnosed in 1998-2013 in the colon or rectum, pancreas, lung, breast, prostate, corpus uteri, ovaries, or urinary bladder, constituting 71% of all cancers diagnosed among Diet, Cancer and Health study participants in the period. We excluded 248 participants with previous hospital contacts for organic mental disorder, mental or behavioral disorder due to use of a psychoactive substance, schizophrenia, schizotypal, or delusional disorder or manic or bipolar episodes 296.19, 296.39, .99 and ICD-10: F00-F31). We also excluded 14 persons not residing in Denmark at diagnosis of cancer, 11 persons with cancer diagnosed simultaneously at two different sites, nine patients with male breast cancer and one person whose date of death was registered before diagnosis of cancer. We were unable to retrieve stored DNA samples from 38 people, leaving a final study population of 7,320. The selection of the study population is illustrated in Supporting Information Figure S1 . We previously reported an investigation of associations between biallelic and triallelic variants of 5-HTTLPR and use of antidepressants for a subset of the current study population, consisting of 806 people with colorectal cancer diagnosed in 1998-2009 (Suppli et al., 2015) .
Data sources
We ensured accurate linkage of our study population with nationwide registries by using the unique personal identification number assigned to all Danish residents since 1968 (Pedersen, 2011) . We obtained the date of diagnosis and type of cancer from the Danish Cancer Registry, which since 1943 has registered cancers diagnosed in Denmark with a high degree of completeness (Gjerstorff, 2011; Storm, Michelsen, Clemmensen, & Pihl, 1997 (Mors, Perto, & Mortensen, 2011) . and all outpatients hospital contacts since 1995 (Lynge, Sandegaard, & Rebolj, 2011) . From the discharge diagnoses, we calculated individual Charlson Comorbidity Index scores at the date of cancer diagnosis. The original index includes 19 diseases assigning each a weighted score representing the 1-year relative risk of dying. We used a modified version not including the index cancer (Charlson, Pompei, Ales, & MacKenzie, 1987; Dalton et al., 2008) .
DNA analyses
Four functional single nucleotide polymorphisms (SNPs) in genes encoding the brain derived neurotrophic factor (BDNF; rs6265) (Chen et al., 2004; Egan et al., 2003) , serotonin receptor 1A (HTR1A; rs6295) (Lemonde et al., 2003) , catechol-O-methyl transferase (COMT; rs4680) (Lachman et al., 1996) , and the FK506-binding protein 5 gene (FKBP5; rs1360780) (Binder et al., 2004) were determined by KASP genotyping with individual genotypes interpreted automatically by relevant software.
Variants in the serotonin transporter linked polymorphic region (5-HTTLPR) were determined by DNA sequencing. We determined the zygosity of long (L) and short (S) alleles visually. For all long alleles, we determined whether an adenine (A) or a guanine (G) was present at the rs25531 locus. Thus, we were able to distinguish biallelic (LL, LS, SS) and triallelic (high:
genotypes according to the transcriptional activity of 5-HTTLPR.
The genotypes of BDNF rs6265 (P = 0.79), HTR1A rs6295 (P = 1.00), COMT rs4680 (P = 0.79), FKBP5 rs1360780 (P = 0.41) and the biallelic 5-HTTLPR (P = 0.79) were all in Hardy-Weinberg equilibrium. The
; SL G , n = 394; SS, n = 1262) were not in Hardy-Weinberg equilibrium (P = 0.001). However, the proportion of L A (51%), L G (7%), and S (42%) alleles were similar to the proportions found in a previous Danish study (Rasmussen, Bagger, Tanko, Christiansen, & Werge, 2009 ) and the distribution according to transcriptional activity (high: 27%, intermediate: 49%, low: 24%) resembles previous observations in Northern European populations (Araya et al., 2009; Bukh et al., 2009; Reinelt et al., 2013) .
Statistical methods
We determined the incidence density rates for use of antidepressants in our study population in the years around the cancer diagnosis with follow-up from 3 years before cancer diagnosis until first prescription of antidepressants, emigration, diagnosis of a second cancer, hospital contact with a diagnosis of severe mental disorder, death, or 5 years after cancer diagnosis, whichever came first.
We assessed differences in sex, age at diagnosis of cancer, sociodemographic characteristics, treatment for depression before cancer, calendar year of cancer diagnosis and type of cancer according to genotype with 2 tests for categorical variables, and analysis of variance for continuous variables.
In primary analyses, we used Cox regression analyses to determine associations between being a heterozygote or a homozygote for the hypothesized risk allele of each genetic variant and use of antidepressants after cancer diagnosis. Homozygotes for the hypothesized nonrisk allele were used as the reference group. This strategy yielded 12 statistical tests, and we decided to apply Bonferroni correction to our analyses, with an of 0.0042. With differences dependent on genotype distributions, this gave us power to detect hazard ratios (HRs) of approximately 1.25.
The secondary analyses included plots of the cumulative incidence of use of antidepressants according to genotype with diagnosis of a second cancer, a hospital contact for severe mental disorder and death as competing risks. Secondary Cox regression analyses were performed to determine associations between genotypes and hospital contacts for depression after diagnosis of cancer. Associations between genotypes and use of antidepressants were analyzed according to time since cancer diagnosis (1-6 months, 7-12 months, 2 years, 3 years, 4-5 years, and 6-8 years). We also determined associations between genotypes and use of antidepressants in models according to sex, cancer prognosis (5-year survival > 80%: prostate, breast, and corpus uteri cancer; 5-year survival 40-70%: ovary, bladder, and colorectal cancer; 5-year survival < 20%: lung and pancreas cancer) and the four major cancer types (prostate, breast, colorectal, and lung).
To determine whether the hypothesized associations were more pronounced for incident depression, we conducted separate Cox analyses After assessing the assumption of proportionality in all Cox models, we included sex and calendar year of cancer diagnosis (continuous variable) as covariates and stratified on age at cancer diagnosis (<60, 60-64, 65-69, 70-74, ≥75 years). In analyses of cumulative incidence of use of antidepressants, we included sex as a covariate and tested differences between genotypes with Gray's test. In Cox models and for cumulative incidence plots, time since diagnosis of cancer was used as the underlying time, and participants were followed until outcome or any of the following censoring events: migration, diagnosis of a second cancer, hospital contact with a diagnosis of severe mental disorder (not including depression), death or 31 December 2013, whichever came first.
We performed 2 tests, analysis of variance, and Cox regression analysis with the FREQ, UNIVARIATE, and PHREG procedures in SAS version 9.3. Cumulative incidence was analyzed with the "cmprsk" package in R version 3.1.2 (Gray, 2014; R Core Team, 2013) .
Ethical considerations
This study was approved by the Committee on Health Research Ethics, Capital Region of Denmark (protocol number H-15005195).
RESULTS
In our study population, incident use of antidepressants increased from 30 new users per 1,000 person-years in the year preceding cancer diagnosis to 87 new users per 1,000 person-years in the year after cancer diagnosis (Fig. 1) . 
TA B L E 1
Differences between genotypes within genetic variants were tested for people successfully genotyped for each variant. We used 2 tests for categorical variables, while calendar year of diagnosis was tested with ANOVA.
In general, baseline characteristics and cancer type were not associated with the genetic variants (Table 1) ; however, the comorbidity score was significantly associated with FKBP5 (P = 0.03).
In the primary analyses, all HR estimates were 0.95-1.07, and none of the genetic variants was statistically significantly associated with risk for use of antidepressants after cancer ( Table 2) . Inclusion of the comorbidity score in the analysis of the FKBP5 did not affect the estimate (results not shown). Further, we found no statistically significant associations between the genetic variants and hospital contact for depression as the first event after cancer (Table 2 ). Cumulative incidence plots showed no statistically significant associations between the investigated genotypes and the probability of use of antidepressants (Fig. 2) . Our Cox analysis of hazard for use of antidepressants according to time since cancer diagnosis revealed no statistically significant results and gave no indication that genetic variants are more likely to be associated with the outcome in periods closer to the diagnosis (Supporting Information Table S1 ).
TA B L E 2
Cox regression analyses by sex, 5-year cancer prognosis (>80%, 40-70%, <20%) and cancer type are shown in Figure 3 . The HRs for use of antidepressants were 0.83-1.31, except for statistically nonsignificantly higher estimates for the AA genotype of the BDNF rs6265 among people with poor-prognosis cancers (HR, 1.76; 99.58% CI, 0.94-3.30), specifically for lung cancer (HR 1.60; 99.58% CI, 0.76-3.38).
However, these estimates were based on only 72 participants with poor-prognosis cancer and the rare AA genotype, of whom 23 were treated with antidepressants.
Cox analyses separated according to treatment for depression before cancer diagnosis showed similar nonsignificant associations of genotypes with antidepressant use after cancer between groups of people not treated and treated for depression before cancer, respectively (Supporting Information Table S2 ).
DISCUSSION
This large study of hypothesized interactions between genetic variants in 5-HTTLPR, BDNF, HTR1A, COMT, and FKBP and stressful life events and the risk for depression indicates that it is unlikely that any of these genetic variants has a clinically relevant individual effect on risk for depression in elderly people diagnosed with cancer.
Previous meta-analyses of the 5-HTTLPR indicated that the hypothesized gene-environment interaction was clearer in studies with objective measurement of stress or medical conditions as stressors (Karg, Burmeister, Shedden, & Sen, 2011; Sharpley et al., 2014) ; however, in the present study of the objectively assessed medical condition of cancer diagnosis, we observed no such interaction. One metaanalysis of the BNDF rs6265, found stronger evidence of an interaction with stressful life events in adults than in children (Hosang et al., 2014) . Our study does not support this hypothesis in older adults.
Previous reports of significant associations between the investigated genetic variants in HTR1A, COMT, and FKBP5, adverse environmental exposure and risk for depression relied on few patients with depression who had the investigated genotype and who were also exposed to stress adverse environmental exposure and risk for depression relied on few patients with depression who had the investigated genotype and who were also exposed to stress (Galvão-de Almeida et al., 2014; Kraus et al., 2007; Lebe et al., 2013; Comasco et al., 2011; Doornbos et al., 2009; Mandelli et al., 2007; Appel et al., 2011; Kang et al., 2012; Lahti et al., 2015; Nyman et al., 2011; Scheuer et al., 2016; Shinozaki et al., 2011; Zimmermann et al., 2011) . Our study, with a large number of cases, does not support an omnipresent existence of interactions between these genetic variants and adverse environmental exposures on risk for depression.
Our population was similar in size to the total number of people evaluated for objectively measured stressful events or medical 
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Time since diagnosis, years Probability of treatment with antidepressants CC CT TT F I G U R E 2 Cumulative incidence plots of probability of use of antidepressants after cancer diagnosis according to genotype among 7,320 people in the Diet, Cancer and Health cohort study with one of eight major cancer types diagnosed in 1998-2013. Diagnosis of second cancer, hospital contact for severe mental disorder (ICD-10: F00-31) and death were included as competing events. Differences between genotypes were tested with Gray's test F I G U R E 3 Forest plot of hazard ratios and 99.58% confidence intervals for use of antidepressants after cancer diagnosis from overall Cox analyses and Cox analyses by sex, cancer prognosis according to 5-year survival and the four most common cancer types, among 7,320 people in the Diet, Cancer and Health cohort study with one of eight major cancer types diagnosed in 1998-2013.The overall estimates plotted with diamonds correspond to the hazard ratio estimates presented in Table 2 . The x-axis of each plot is on a logarithmic scale. Hazard ratio estimates on the right side of the reference value of 1 indicate higher risk for use of antidepressants associated with hypothesized risk alleles conditions in the most recent, largest meta-analysis of 5-HTTLPR (Sharpley et al., 2014) and corresponds to the total number of people in studies of the interaction between adult stressful life events and BDNF rs6265 polymorphism in another meta-analysis (Hosang et al., 2014) . In addition, with this study, we approximately doubled the total number of people investigated for interactions between each of the selected genetic variants in COMT, HTR1A and FKBP5 and adverse environmental exposures on risk for depression.
Our study overcame several fundamental challenges in studying gene-environment interactions (Thomas, 2010) . First, we identified cancer diagnoses in a nationwide, virtually complete register and thus accurately ascertained the occurrence and timing of a severely stressful life event with no recall bias. As a cancer diagnosis implies an increased risk for death and also often involves intense, severe treatment with serious acute, enduring side effects, we consider that it is a stressful life event with an objective negative impact and long-term contextual threat, as proposed by Paykel (1983) , Brown and Harris (1978) and more recently Kendler, Karkowski, and Prescott (1998) . Accordingly, and in line with previous reports (Massie, 2004; Mitchell et al., 2011; van't Spijker et al., 1997) , we observed increased use of antidepressants after diagnosis of cancer in this study. Second, we used antidepressant use as the observer-based measure of depression recognized and pharmacologically treated by a physician as well as hospital contacts for depression as a measure of the most severe depression, which allowed longitudinal assessment of depression and investigation of hypothesized interactions with survival analyses and competing risk analyses. Third, by applying an exposed-only design, we focused on people in whom the effect of the investigated genetic variants on risk for depression is hypothesized to be present, maximizing statistical power. Thus, a unique feature of the present study is that the results are based on hundreds of events in strata of genotype by stress exposure. Further, the exposed-only design allowed us to sidestep controversial issues involved in distinguishing biological versus statistical interaction as well as additive versus multiplicative interactions (Karg et al., 2012; Kendler et al., 2010; Moffitt, Caspi, and Rutter, 2006; Rutter et al., 2009) . Fourth, our population was ethnically homogeneous, reducing the risk for bias due to population stratification. However, a limitation of our study population is that participants in the Diet, Cancer and Health study were generally socioeconomically privileged (Larsen et al., 2012) and probably had higher health literacy. Thus, our results might not be generalizable to populations that are less health literate.
Further limitations of our study include the fact that use of antidepressants as a measure of pharmacologically treated depression introduces some misclassification, as all cases of depression are not diagnosed and pharmacologically treated; for those that are treated, the median lag between onset of depression and diagnosis and possible treatment initiation is about 1 year (Wang et al., 2007) . Further, although depression is the indication for about 75% of all prescribed antidepressants, these drugs are also prescribed for other indications, primarily anxiety and pain (Charles, Britt, Fahridin, & Miller, 2007; Loosbrock, Tomlin, Robinson, Obenchain, & Croghan, 2002; Trifiro et al., 2013) . Nevertheless, we consider that any misclassification introduced by use of antidepressants as our primary outcome measure would be nondifferential and was unlikely to result in failure to observe any clinically relevant, true association between the investigated genetic variants and risk for depression. In addition, the Some limitations also apply to use of a cancer diagnosis as a stressful life event. Thus, although we assumed that this was a stressful event for all the people included in this study, we did not assess the level of stress individually. Further, we used diagnosis of cancer as the baseline in our analysis, whereas physical symptoms and worry are probably present in the months preceding this date. Addition of an instrument such as the Interview for Recent Life Events, in which the time of occurrence, the independence of the depressive state, and the negative impact of the event are rated by an interviewer, might have clarified the individual level of stress posed by a diagnosis of cancer Paykel, 1997) . A central concern in studies of the association between stressful life events and risk for depression, including studies of geneenvironment interactions, is whether people prone to depression are more likely to expose themselves to the studied life events (Kendler, Karkowski, & Prescott, 1999) . We showed previously that, although depression is generally not associated with an increased risk for cancer, people with depression are at increased risk for tobacco-related cancers (cancers of the urinary bladder, lung, and pancreas) (Dalton, Mellemkjaer, Olsen, Mortensen, & Johansen, 2002) . In our study, 72% of the population had nontobacco-related cancers (prostate, breast, corpus uteri, ovarian, and colorectal cancers), and analyses separated by cancer type did not indicate different associations between cancer types. Furthermore, the genotype distribution was identical for all cancer types.
The triallelic 5-HTTLPR genotype was not in Hardy-Weinberg equilibrium, indicating that our DNA analysis of this genetic variant was imperfect. As the disequilibrium was primarily the consequence of a higher than expected number of participants with the rare L G L G genotype we reassessed the sequencing data for people with this genotype without finding reason to question the original calls. Thus, we consider it a minor limitation of our study that the triallelic 5-HTTLPR genotype was not in Hardy-Weinberg equilibrium.
The similarity of the inflammatory processes observed in both tumor growth and depression (Sotelo, Musselman, & Nemeroff, 2014) possibly limits the generalizability of our results. Some of the increased incidence of depression after a diagnosis of cancer might be directly linked to inflammatory processes related to tumorigenesis, thus bypassing the higher order brain functions hypothesized to transduce psychosocial stress into depressive episodes (Slavich et al., 2014) .
In addition, our results are not necessarily generalizable to adversity in childhood or stressful life events in early adulthood. It is plausible that the biological mechanisms-including gene-environment interactions-involved in the increased risk for and poorer prognosis of adult depression associated with childhood adversity are specific to the sensitive periods of the maturing brain in early life (Andersen et al., 2008; Brown et al., 2008; Heim et al., 2012) . Accordingly, Brown and Harris hypothesized that an effect of the 5-HTTLPR on risk for depression after adult stressful life events would be present only among individuals exposed to childhood maltreatment (Brown et al., 2008) . This hypothesis could account for the lack of positive findings for the other genetic variants included in this study, as well. A previous study found that 5-HTTLPR interacted with childhood maltreatment specifically on the risk for persistent depression but not for single-episode depression in young adults (Uher et al., 2011) , indicating that gene-environment interactions can affect only certain types or severity of depression. In the present study, neither analyses by treatment for depression before cancer nor analyses with hospital contacts for depression as a proxy measures for more severe depression indicated such differences.
Finally, as outlined by Keller, a number of statistical concerns have caused skepticism about the validity of previous positive findings of gene-environment interaction (Keller, 2014) . Accordingly, it is possible that our presently reported negative findings are simply due to a nonexistence of the originally hypothesized involvement of the selected genetic variants in gene-environment interaction for depression.
CONCLUSION
We find it unlikely that any of the genetic variants we investigated have clinically relevant individual effects on the risk for depression after a diagnosis of cancer, and our results do not support hypotheses that these genetic variants interact with stressful life events to cause depression in elderly people.
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